ALID

AlliedOTCPK:ALID Stock Report

Market Cap

US$151.0m

7D

9.3%

1Y

25.3%

Updated

19 Sep, 2021

Data

Company Financials
ALID fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

ALID Overview

Allied Corp., a medical cannabis production company, engages in the research, development, and production of cannabinoid health solutions in the United States.

Share Price & News

How has Allied's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALID is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 20% a week.

Volatility Over Time: ALID's weekly volatility has decreased from 29% to 20% over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

9.3%

ALID

-2.5%

US Pharmaceuticals

-0.6%

US Market


1 Year Return

25.3%

ALID

11.0%

US Pharmaceuticals

33.8%

US Market

Return vs Industry: ALID exceeded the US Pharmaceuticals industry which returned 11% over the past year.

Return vs Market: ALID underperformed the US Market which returned 33.8% over the past year.


Shareholder returns

ALIDIndustryMarket
7 Day9.3%-2.5%-0.6%
30 Day66.4%-8.5%1.0%
90 Day84.3%-0.2%3.4%
1 Year25.3%25.3%15.6%11.0%35.8%33.8%
3 Yearn/a20.3%10.1%60.0%50.1%
5 Yearn/a49.9%30.5%123.0%98.7%

Long-Term Price Volatility Vs. Market

How volatile is Allied's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Allied Fundamentals Summary

How do Allied's earnings and revenue compare to its market cap?
ALID fundamental statistics
Market CapUS$150.98m
Earnings (TTM)-US$10.55m
Revenue (TTM)US$5.26k

31.3kx

P/S Ratio

-14.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALID income statement (TTM)
RevenueUS$5.26k
Cost of RevenueUS$227.26k
Gross Profit-US$222.00k
ExpensesUS$10.33m
Earnings-US$10.55m

Last Reported Earnings

May 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.13
Gross Margin-4,220.47%
Net Profit Margin-200,530.23%
Debt/Equity Ratio116.3%

How did ALID perform over the long term?

See historical performance and comparison

Valuation

Is Allied undervalued compared to its fair value and its price relative to the market?

53.65x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALID's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALID's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALID is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: ALID is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALID's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALID is overvalued based on its PB Ratio (53.7x) compared to the US Pharmaceuticals industry average (3.2x).


Future Growth

How is Allied forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Allied has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Allied performed over the past 5 years?

-234.4%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: ALID is currently unprofitable.

Growing Profit Margin: ALID is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ALID's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ALID's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALID is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: ALID has a negative Return on Equity (-374.76%), as it is currently unprofitable.


Financial Health

How is Allied's financial position?


Financial Position Analysis

Short Term Liabilities: ALID's short term assets ($1.6M) do not cover its short term liabilities ($4.8M).

Long Term Liabilities: ALID's short term assets ($1.6M) exceed its long term liabilities ($67.1K).


Debt to Equity History and Analysis

Debt Level: ALID's debt to equity ratio (116.3%) is considered high.

Reducing Debt: Insufficient data to determine if ALID's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALID has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: ALID is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.


Dividend

What is Allied current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALID's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALID's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALID's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALID's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALID's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

US$48k

CEO Compensation


CEO

Calum Hughes

no data

Tenure

US$48,000

Compensation

Mr. Calum Hughes serves as Founder, Chairman, Chief Executive Officer and Director of Allied Corp. He has been responsible for leading activities relating to large scale Quality Assurance and Evaluation of...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Allied Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Allied Corp.
  • Ticker: ALID
  • Exchange: OTCPK
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$150.981m
  • Shares outstanding: 80.31m
  • Website: https://allied.health

Location

  • Allied Corp.
  • 1405 St. Paul Street
  • Suite 201
  • Kelowna
  • British Columbia
  • V1Y 2E4
  • Canada

Listings


Biography

Allied Corp., a medical cannabis production company, engages in the research, development, and production of cannabinoid health solutions in the United States. It offers hemp derived natural health product...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/19 22:16
End of Day Share Price2021/09/17 00:00
Earnings2021/05/31
Annual Earnings2020/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.